Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1438-1445

  Adjei, A A ^a   Davis, J N ^a   Bruzek, L M ^a   Erlichman, C ^a   Kaufmann, S H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; LONAFARNIB; MELPHALAN; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CISPLATIN; DNA ADDUCTS; DRUG COMBINATIONS; DRUG SYNERGISM; FLUOROURACIL; HUMANS; MELPHALAN; PIPERIDINES; PLATINUM; PYRIDINES; TUMOR CELLS, CULTURED;

EID: 0034905234     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues
2. Human lamin B contains a farnesylated cysteine residue
3. The processing pathway of prelamin A
4. FTIs block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
5. Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome
6. In vivo differential prenylation of retinal cyclic GMP phosphodiesterase catalytic subunits
7. Isoprenylation of a protein kinase. Requirement of farnesylation/α-carboxyl methylation for full enzymatic activity of rhodopsin kinase
8. PxF a prenylated protein of peroxisomes
9. Characterization of HDJ-2, a human 40 kD heat shock protein
10. The γ subunit of transducin is farnesylated
11. Ras Signaling and apoptosis
12. Ras oncogenes in human cancer: A review
13. Isoprenoid addition to ras proteins is the critical modification for its membrane association and transforming activity
14. Ras and leukemia: From basic mechanisms to gene-directed therapy
15. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
16. Targeting the Ras signaling pathway: A rational mechanism-based treatment for hematologic malignancies?
17. Farnesyltransferase inhibitors versus Ras inhibitors
18. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
19. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB
20. Cell-growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
21. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesylation inhibitors
22. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
23. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice
24. Clinical trials referral resource. Clinical trials with the farnesyl transferase inhibitor R115777
25. A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
26. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to Taxol and epothilones
27. Antitumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-Ras transgenic mice
28. Antitumor efficacy of a novel class of non-Thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine
29. 1 block in p53 wild-type tumor cells
30. Comparison of potential markers of farnesyltransferase inhibition
31. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: Inhibition of platinum-DNA adduct removal
32. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
33. Murine pharmacokinetics of 6-aminonicotinamide: A novel biochemical modulating agent
34. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: Importance of sequence of administration
35. Methods used to study apoptosis
36. Phase I and pharmacologic study of continuous daily oral SCH66336: A novel farnesyl transferase inhibitor in patients with solid tumors
37. Infusional 5-FU: Historical evolution, rationale, and clinical experience
38. The search for synergy: A critical review from a response surface perspective
39. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation
40. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II: Prevention of cleavable complex formation
41. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin
42. Cell-cycle arrest versus cell death in cancer therapy
43. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
44. Loss of DNA mismatch repair in acquired resistance to cisplatin
45. Cisplatin and Adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line
46. Platinum analogues
47. Plasma levels and urinary excretion of filterable platinum species following bolus injection and IV infusion of Cis-dichlorodiammineplatinum (II) in man